AB 1016 would establish a Rare Disease Advisory Council that would give patients a voice in state government and provide educational resources for elected leaders on critical issues related to access, coverage, and the diseases themselves.
On behalf of our membership and California’s statewide life sciences community – a sector which employs over 311,000 Californians – California Life Sciences Association (CLSA) welcomes Congressman Josh Harder (D-Turlock). We look forward to working with Congressman Harder and his team to advance policies that improve patient health and bring positive change for California patients and their families.
On behalf of our membership and California’s statewide life sciences community – a sector which employs over 311,000 Californians – California Life Sciences Association (CLSA) welcomes State Senator Brian Jones (R-Santee). We look forward to working with Senator Jones and his team to advance policies that improve patient health and bring positive change for California patients and their families.
On behalf of our membership and California’s statewide life sciences community – a sector which employs over 311,000 Californians – California Life Sciences Association (CLSA) welcomes Assemblymember Jesse Gabriel (D–Encino). We look forward to working with Assemblymember Gabriel and his team to advance policies that improve patient health and bring positive change for California patients and their families.
On behalf of our membership and California’s statewide life sciences community – a sector which employs over 311,000 Californians – California Life Sciences Association (CLSA) welcomes Congressman Harley Rouda (D-Laguna Beach). We look forward to working with Rep. Rouda and his team to advance policies that improve patient health and bring positive change for California patients and their families.
On behalf of our membership and California’s statewide life sciences community – a sector which employs over 311,000 Californians – California Life Sciences Association (CLSA) welcomes State Senator Ling Ling Chang (R-Diamond Bar). We look forward to working with Senator Chang and her team to advance policies that improve patient health and bring positive change for California patients and their families.
In November 2018, the Trump Administration proposed a rule that would weaken patient protections within Medicare’s Part D prescription drug benefit. Currently, Medicare Part D drug plans are required to comply with the “protected drug classes” policy, which ensure that beneficiaries have access to “all or substantially all” drugs in six specific classes of medicines (like antiretrovirals, antidepressants, antipsychotics, and anticonvulsant agents).
On behalf of our membership and California’s statewide life sciences community – a sector which employs over 311,000 Californians – California Life Sciences Association (CLSA) welcomes Assemblyman James Ramos (D-Highland). We look forward to working with Assemblyman Ramos and his team to advance policies that improve patient health and bring positive change for California patients and their families.